DOI: https://doi.org/10.22141/2224-1485.3-4.64-65.2019.177844

Modern symptomatic therapy for stable angina pectoris: what to choose?

Yu.M. Sirenko, O.O. Torbas

Abstract


Coronary heart disease is the second most common cardiovascular disease in the world and in Ukraine after hypertension, and therefore, the management of patients with hypertension and сoronary heart disease is a task not only for the cardiologist, but also for the physician at any level of medical care provision. Symptomatic treatment of stable angina, which involves the relief and prevention of the chest pain (or angina equivalents) in patients with сoronary heart disease, remains an actual strategy in cases where angina attacks remain even despite of optimally chosen therapy, revascularization is not possible, and the subsequent titration of the first-line drugs is not possible due to the risk of adverse effects. The leading place among the second-line drugs with anti-ischemic effects, which are used to eliminate angina attacks, belongs to short and prolonged forms of nitrates that provide coronary arterial vasodilatation through the activation of the active component, nitric oxide. A prolonged form of isosorbide dinitrate is prescribed most often to prevent angina attacks. The convenient dosing regimen provides, on the one hand, a prolonged effect and, on the other hand, helps to reduce the risk of tolerance to nitrates. However, in practice we can observe the appearance of such complication as headache. In order to avoid this, the practitioner quite often makes a choice in favor of molsidomine. But it has been shown that the antianginal effect of this drug is much lower than that of prolonged forms of nitrates. In Ukraine, molsidomine is prescribed not in the dose for which the antianginal effect (16 mg) was proved, but in a significantly lower one. It has been shown that linsidomine, molsidomine metabolite, is characterized by a significant toxicity, and therefore, many countries refused using molsidomine. The prescription of prolonged forms of nitrates is the most optimal tactic.

Keywords


coronary heart disease; stable angina pectoris; symptomatic therapy; nitrates; molsidomine

References


European Cardiovascular Disease Statistics 2017 edition report.

Державна служба статистики. Україна у цифрах 2017: статистичний збірник. Київ, 2018.

Наказ Міністерства охорони здоров’я України № 152 від 02.03.2016 «Про затвердження та впровадження медико-технологічних документів зі стандартизації медичної допомоги при стабільній ішемічній хворобі серця» (зі змінами від 23.09.2016, наказ № 994).

Наказ Міністерства охорони здоров’я України № 1422 від 29 грудня 2016 року «Про внесення змін до наказу Міністерства охорони здоров’я України від 28 вересня 2012 року № 751».

Task Force Members. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the ma-nagement of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 2013 Oct. 34(38). 2949-3003. doi: 10.1093/eurheartj/eht296. Epub 2013 Aug 30.

Updated future 2019 ESC Guidelines on the management of ‘chronic coronary syndromes’ to replace prior ESC Guidelines on ‘stable coronary artery disease’ ESC Congress News 2018 — Munich, Germany. 27 Aug 2018.

Whelton P.K. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018 Oct 23. 138(17). e426-e483.

Williams B. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardio-logy and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J. Hypertens. 2018 Oct. 36(10). 1953-2041.

Лутай М.І., Пархоменко О.М., Лисенко А.Ф., Голікова І.П. Пацієнт зі стабільною ІХС в Україні та Європі: результати 5-річного реєстру CLARIFY. УКЖ. 2018. 4. 19-30.

Young J.W. Jr, Melander S. Evaluating Symptoms to Improve Quality of Life in Patients with Chronic Stable Angina. Nurs. Res Pract. 2013. 2013. 504915.

Longmore R.B., Spertus J.A., Alexander K.P. Angina frequency after myocardial infarction and quality of life in older versus younger adults: the Prospective Registry Evaluating Myocardial Infarction: Event and Recovery study. Am. Heart J. 2011 Mar. 161(3). 631-8.

Mollon L., Bhattacharjee S. Health related quality of life among myocardial infarction survivors in the United States: a propensity score matched analysis. Health Qual. Life Outcomes. 2017. 15. 235.

Grodzinsky A., Arnold S.V., Gosch K. et al. Angina frequency after acute myocardial infarction in patients without obstructive coronary artery disease. Eur. Heart J. Qual. Care Clin. Outcomes. 2015 Nov. 1(2). 92-99.

Fanaroff A.C., Kaltenbach L.A., Peterson E.D. et al. Ma-nagement of Persistent Angina After Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study. J. Am. Heart Assoc. 2017 Oct 19. 6(10).

Brorsson B., Bernstein S.J., Brook R.H. et al. Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart. 2002 Feb. 87(2). 140-145.

Нормативно-директивні документи МОЗ України / Лікарські засоби.

WHO Collaborating Centre for Drug Statistacs Methodo-logy. ATC/DDD Index 2019.

Наказ Міністерства охорони здоров’я України від 10.05.2018 № 868. Державний формуляр лікарських засобів. Випуск 10.

Schelling J.L., Lasagna L. A study of cross-tolerance to circulatory effects of organic nitrates. Clin. Pharmacol. Ther. 1967 Mar-Apr. 8(2). 256-60.

Parker J.O., Fung H.L., Ruggirello D. et al. Tolerance to isosorbide dinitrate: rate of development and reversal. Circulation. 1983 Nov. 68(5). 1074-80.

Rosenkranz B., Winkelmann B.R., Parnham M.J. Clinical pharmacokinetics of molsidomine. Clin. Pharmacokinet. 1996 May. 30(5). 372-84.

Reden J. Molsidomine. Blood Vessels. 1990. 27(2-5). 282-94.

Scholtholt J., Fiedler V.B., Keil M. Effect of molsidomine on the regional distribution of cardiac output in the anaesthetized dog. Arzneimittelforschung. 1978. 28(9). 1612-9.

Majid P.A., DeFeyter P.J., Van der Wall E.E. Molsidomine in the treatment of patients with angina pectoris. N. Engl. J. Med. 1980 Jan 3. 302(1). 1-6.

Singlas E., Martre H. Human pharmacokinetics of molsidomine. Ann. Cardiol. Angeiol. (Paris). 1983 Dec. 32(8). 503-9.

Rudolph W., Dirschinger J. Effectiveness of molsidomine in the long-term treatment of exertional angina pectoris and chronic congestive heart failure. Am. Heart J. 1985 Mar. 109 (3 Pt 2). 670-4.

Messin R., Boxho G., De Smedt J. Acute and chronic effect of molsidomine extended release on exercise capacity in patients with stable angina, a double-blind cross-over clinical trial versus placebo. J. Cardiovasc. Pharmacol. 1995 Apr. 25(4). 558-63.

Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris (MEDCOR). ClinicalTrials.gov Identifier: NCT01363661.

Messin R., Cerreer-Bruhwyler F., Dubois C. Efficacy and safety of once- and twice-daily formulations of molsidomine in patients with stable angina pectoris: double-blind and open-label studies. Adv. Ther. 2006 Jan-Feb. 23(1). 107-30.

U.S. Food and Drug Administration. Orange Book.

Drug Central. FDA Adverse Event Reporting System. Online Drug Compendium.

Kyeong Hye Jeong, Euni Lee. A Systematic Review on Drug Safety for Molsidomine, Nicorandil and Trimetazidine. Korean J. Clin. Pharm. 2016. 26(2). 172-180.




Copyright (c) 2019 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2019

 

   Seo анализ сайта